<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04117555</url>
  </required_header>
  <id_info>
    <org_study_id>5956-19</org_study_id>
    <nct_id>NCT04117555</nct_id>
  </id_info>
  <brief_title>Assessment of Pupil Light Responses in Patients With Parkinson Disease</brief_title>
  <official_title>Assessment of Pupil Light Reflex in Patients With Parkinson Disease in Comparison to Healthy Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Parkinson diseases (PD) is the second most common degenerative disease of the central nervous&#xD;
      system. The development of early diagnostic biomarkers may help identify at-risk individuals&#xD;
      and allow precocious interventions at the onset of disease and more precise monitoring of&#xD;
      therapies that may slow disease progression.&#xD;
&#xD;
      Proof of concept studies indicated significant differences in pupil light response between PD&#xD;
      patients and healthy controls. The feasibility of using pupillometry for assesment of PD will&#xD;
      be examined.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pupillometry</measure>
    <time_frame>1 day</time_frame>
    <description>Pupil response to light stimuli</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>1day</time_frame>
    <description>Visual Acuity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Color vision</measure>
    <time_frame>1 day</time_frame>
    <description>Color vision by Farnsworth/Lanthon D-15 Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Humphrey 24-2 perimetry</measure>
    <time_frame>1 day</time_frame>
    <description>Visual field will be assessed by Humphrey 24-2 perimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spcetral Domain Optical Coherence Tomography (SD-OCT)</measure>
    <time_frame>1 day</time_frame>
    <description>Optic nerve and retinal structure will be assessed by SD-OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual evoked potential</measure>
    <time_frame>1 day</time_frame>
    <description>Occipital cortex function will be assessed by visual evoked potential (VEP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Pupillometry at 1 year</measure>
    <time_frame>Single visit: 1 day, 1 year after baseline testing</time_frame>
    <description>Change from baseline in pupil response to light stimuli at 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline best corrected visual acuity at 1 year</measure>
    <time_frame>Single visit: 1 day, 1 year after baseline testing</time_frame>
    <description>Change from baseline visual acuity at 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline color vision at 1 year</measure>
    <time_frame>Single visit: 1 day, 1 year after baseline testing</time_frame>
    <description>Change from baseline color vision by Farnsworth/Lanthon D-15 at 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Humphrey 24-2 at 1 year</measure>
    <time_frame>Single visit: 1 day, 1 year after baseline testing</time_frame>
    <description>Change from baseline Humphrey 24-2 visual field at 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline SD-OCT at 1 year</measure>
    <time_frame>Single visit: 1 day, 1 year after baseline testing</time_frame>
    <description>Change from baseline optic nerve and retinal structure by SD-OCTat 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline visual evoked potential at 1 year</measure>
    <time_frame>Single visit: 1 day, 1 year after baseline testing</time_frame>
    <description>Change from baseline occipital cortex function by visual evoked potential testing to at 1 year</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Diagnostic Test: Pupillometry</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parkinson patients</arm_group_label>
    <description>Diagnostic Test: Pupillometry</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Pupil response to light stimuli</intervention_name>
    <description>Objective and accurate measurement of pupillary responses to light stimuli</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Parkinson patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        One hundred Parkinson patients or patients with parkinsonism and 100 age-matched controls&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  General inclusion criteria&#xD;
&#xD;
               1. Age 30-75 years old&#xD;
&#xD;
               2. Signed written informed consent&#xD;
&#xD;
               3. Gender: Both (Male and Female)&#xD;
&#xD;
               4. Pupillary reflex to light.&#xD;
&#xD;
               5. Clear ocular media&#xD;
&#xD;
        Patients' Inclusion Criteria:&#xD;
&#xD;
        Patients with clinical presentations of the neurodegenerative forms of parkinsonism&#xD;
        (bradykinesia, extrapyramidal rigidity, tremor, postural instability and gait disturbance)&#xD;
        including: idiopathic Parkinson disease (PD), Lewy body disease (LBD), progressive&#xD;
        supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal degeneration (CBD)&#xD;
        and secondary parkinsonisms.&#xD;
&#xD;
        Control group- inclusion criteria&#xD;
&#xD;
          1. Normal eye examination&#xD;
&#xD;
          2. Best-corrected visual acuity (BCVA) of 20/20&#xD;
&#xD;
          3. Normal color vision test (Farnsworth/Lanthon D-15 Test)&#xD;
&#xD;
          4. No present ocular disease&#xD;
&#xD;
          5. No past ocular disease or surgery within last 6 months&#xD;
&#xD;
          6. No use of any topical or systemic medications that could adversely influence efferent&#xD;
             pupil movements&#xD;
&#xD;
          7. Normal 24-2 Humphrey visual field and&#xD;
&#xD;
               -  Short duration (â‰¤10 minutes)&#xD;
&#xD;
               -  Minimal fixation losses, False positive errors and False negative errors (less&#xD;
                  than 30% for each one of reliability indices)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of dementia.&#xD;
&#xD;
          2. Cognitive decline that may impair obtaining informed consent.&#xD;
&#xD;
          3. Tremor or dyskinesia that could interfere with ophthalmic evaluation&#xD;
&#xD;
          4. History of past (last 3 months) or present ocular disease or ocular surgery&#xD;
&#xD;
          5. Use of any topical or systemic medications that could adversely influence pupillary&#xD;
             reflex&#xD;
&#xD;
          6. Psychiatric illness, active psychosis.&#xD;
&#xD;
          7. Previous neurosurgical interventions, including stereotactic neurosurgical procedures.&#xD;
&#xD;
          8. Past or current strokes or brain injury and other brain disorders (except&#xD;
             PD/parkinsonism for patient group)&#xD;
&#xD;
          9. Anti-dopaminergic drugs.&#xD;
&#xD;
         10. Intolerance to gonioscopy, slit lamp examination, Goldmann applanation tomometry or&#xD;
             other schedule study procedure.&#xD;
&#xD;
         11. Visual media opacity including cloudy corneas.&#xD;
&#xD;
         12. Any condition preventing accurate measurement or examination of the pupil.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Sharon Hassin-Baer, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheba Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lori Gueta</last_name>
    <phone>972527485888</phone>
    <email>Lori.Gueta@sheba.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Goldschleger Eye Research Institute, Sheba Medical Center,</name>
      <address>
        <city>Tel HaShomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Gueta</last_name>
      <phone>972-52-7485888</phone>
      <email>Lori.Gueta@sheba.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 18, 2019</study_first_submitted>
  <study_first_submitted_qc>October 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 7, 2019</study_first_posted>
  <last_update_submitted>November 16, 2020</last_update_submitted>
  <last_update_submitted_qc>November 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Sharon Hassin</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

